CEO video on Novo Alzheimer's trial
In this video, ACW CEO Dr Steven Gourlay provides commentary on the implications of the November 24, 2025 announcement from Novo Nordisk regarding its two trials of semaglutide for Alzheimer’s disease.
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Actinogen. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Actinogen a question about this update.